How to Buy Procter & Gamble Health Ltd Shares?
You can easily buy the stocks/shares of Procter & Gamble Health Ltd (PGHL) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Procter & Gamble Health Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of PGHL as on 15th May 2025 is ₹5233.40What is the return on Procter & Gamble Health Ltd share?
The past returns of Procter & Gamble Health Ltd (PGHL) share are- Past 1 week: N/A
- Past 1 month: N/A
- Past 3 months: 11.12
- Past 6 months: 8.84
- Past 1 year: 18.21
- Past 3 years: 49.45
- Past 5 years: 42.00
What is the Dividend yield % on Procter & Gamble Health Ltd share?
The current dividend yield of Procter & Gamble Health Ltd (PGHL) is 4.37What is the Market Cap of Procter & Gamble Health Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Procter & Gamble Health Ltd (PGHL) is ₹9878.29Cr as of 15th May 2025What is the 52 Week High and Low of Procter & Gamble Health Ltd?
The 52-week high and low of Procter & Gamble Health Ltd (PGHL) is ₹6175.50 and ₹4863.What is the PE and PB ratio of Procter & Gamble Health Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Procter & Gamble Health Ltd are 49.15 and 18.35 respectively.Which sector does Procter & Gamble Health Ltd belong to?
Procter & Gamble Health Ltd (PGHL) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Procter & Gamble Health Ltd?
The peers or stocks similar to Procter & Gamble Health Ltd are: and many others.Can't decide whether or not to buy Procter & Gamble Health Ltd?
Worry no more! Login to Tickertape and check out Procter & Gamble Health Ltd (PGHL) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Procter & Gamble Health Ltd?
The 52-week high and low of Procter & Gamble Health Ltd (PGHL) is ₹6175.50 and ₹4863.1. Test Stocks FAQ for Procter & Gamble Health Ltd Shares?
You can easily buy the stocks/shares of Procter & Gamble Health Ltd (PGHL) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Procter & Gamble Health Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of PGHL as on 15th May 2025 is ₹5233.40
Procter & Gamble Health Ltd
PGHL Share Price
5,233.400.04% (+1.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PGHL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PGHL Performance & Key Metrics
PGHL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.33 | 18.35 | 4.37% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.65 | 6.54 | 0.85% |
PGHL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PGHL Company Profile
Procter & Gamble Health Limited, formerly Merck Limited, is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments
SUNPHARMA
PE Ratio
36.18
36.18
1Y Return
13.20%
13.20%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
22.95
22.95
1Y Return
2.92%
2.92%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
19.32
19.32
1Y Return
10.98%
10.98%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.15
57.15
1Y Return
10.81%
10.81%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
48.88
48.88
1Y Return
4.22%
4.22%
Buy Reco %
—
—
PGHL Sentiment Analysis
PGHL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
PGHL Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
PGHL Stock Growth Drivers
PGHL Stock Growth Drivers
0
Hmm, looks like there are nogrowth drivers
PGHL Stock Challenges
PGHL Stock Challenges
1Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
PGHL Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
PGHL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PGHL
PGHL
Income
Balance Sheet
Cash Flow
Annual Normal View
PGHL Income Statement
PGHL Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,424.75 | 1,026.83 | 1,127.60 | 1,248.01 | 1,166.89 | 1,230.53 | ||||||
Raw Materials | 444.47 | 310.39 | 344.55 | 358.99 | 329.69 | 871.60 | ||||||
| Power & Fuel Cost | 19.09 | 12.97 | 14.70 | 12.88 | 8.50 | |||||||
| Employee Cost | 182.93 | 153.66 | 167.56 | 206.17 | 215.16 | |||||||
| Selling & Administrative Expenses | 257.28 | 173.99 | 203.91 | 196.86 | 181.66 | |||||||
| Operating & Other expenses | 136.68 | 111.70 | 116.01 | 130.04 | 130.44 | |||||||
EBITDA | 384.30 | 264.12 | 280.87 | 343.07 | 301.44 | 358.93 | ||||||
| Depreciation/Amortization | 29.45 | 30.04 | 27.08 | 28.10 | 27.40 | 23.85 | ||||||
| PBIT | 354.85 | 234.08 | 253.79 | 314.97 | 274.04 | 335.08 | ||||||
| Interest & Other Items | 0.00 | 0.80 | 0.42 | 0.77 | 0.72 | 0.63 | ||||||
| PBT | 354.85 | 233.28 | 253.37 | 314.20 | 273.32 | 334.45 | ||||||
| Taxes & Other Items | 100.77 | 56.48 | 60.85 | 84.73 | 72.34 | 83.26 | ||||||
| Net Income | 254.08 | 176.80 | 192.52 | 229.47 | 200.98 | 251.19 | ||||||
| EPS | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 151.32 | ||||||
| DPS | 230.00 | 130.00 | 52.50 | 95.00 | 260.00 | 140.00 | ||||||
| Payout ratio | 1.50 | 1.22 | 0.45 | 0.69 | 2.15 | 0.93 |
PGHL Company Updates
FY 2025FY 2025
Investor Presentation
Jun 16PDF
PGHL Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
PGHL Past Performance & Peer Comparison
PGHL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Procter & Gamble Health Ltd | 49.15 | 18.35 | 4.37% |
| Sun Pharmaceutical Industries Ltd | 36.18 | 5.89 | 0.97% |
| Cipla Ltd | 22.95 | 4.51 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.32 | 3.87 | 0.61% |
PGHL Stock Price Comparison
Compare PGHL with any stock or ETFCompare PGHL with any stock or ETF
PGHL
PGHL Holdings
PGHL Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
PGHL Promoter Holdings Trend
PGHL Promoter Holdings Trend
PGHL Institutional Holdings Trend
PGHL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PGHL Shareholding Pattern
PGHL Shareholding Pattern
PGHL Shareholding History
PGHL Shareholding History
Foreign Institutions
Mutual Funds Invested in PGHL
Mutual Funds Invested in PGHL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Procter & Gamble Health Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 4.3017% | Percentage of the fund’s portfolio invested in the stock 0.67% | Change in the portfolio weight of the stock over the last 3 months 0.67% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 43/236 (+23) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.0230% | Percentage of the fund’s portfolio invested in the stock 2.42% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/131 (-64) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3278% | Percentage of the fund’s portfolio invested in the stock 4.70% | Change in the portfolio weight of the stock over the last 3 months 4.70% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 4/52 (+26) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PGHL stock
smallcases containing PGHL stock
Looks like this stock is not in any smallcase yet.
PGHL Events
PGHL Events
PGHL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 4.37%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹43.69 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
PGHL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 4.37%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹43.69 every year
PGHL Upcoming Dividends
PGHL Upcoming Dividends
No upcoming dividends are available
PGHL Past Dividends
PGHL Past Dividends
Cash Dividend
Ex DateEx DateFeb 21, 2025
Interim
Interim | Div/Share: ₹80.00
Dividend/Share
₹80.00
Ex DateEx Date
Feb 21, 2025
Cash Dividend
Ex DateEx DateNov 28, 2024
Final
Final | Div/Share: ₹60.00
Dividend/Share
₹60.00
Ex DateEx Date
Nov 28, 2024
Cash Dividend
Ex DateEx DateFeb 13, 2024
Special
Special | Div/Share: ₹150.00
Dividend/Share
₹150.00
Ex DateEx Date
Feb 13, 2024
Cash Dividend
Ex DateEx DateFeb 13, 2024
Interim
Interim | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Feb 13, 2024
Cash Dividend
Ex DateEx DateNov 22, 2023
Final
Final | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Nov 22, 2023
PGHL Stock News & Opinions
PGHL Stock News & Opinions
Articles & Videos
Corporate
Board of Procter & Gamble Health recommends final dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 45 per equity Share (i.e. 450%) , subject to the approval of the shareholders.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 31.40% in the March 2025 quarter
Net profit of Procter & Gamble Health rose 31.40% to Rs 61.18 crore in the quarter ended March 2025 as against Rs 46.56 crore during the previous quarter ended March 2024. Sales rose 23.17% to Rs 310.99 crore in the quarter ended March 2025 as against Rs 252.48 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales310.99252.48 23 OPM %26.0226.71 - PBDT83.9069.56 21 PBT78.5362.72 25 NP61.1846.56 31 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Procter & Gamble Health declare Quarterly Result
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales309.77309.97 0 OPM %39.8532.79 - PBDT127.24106.64 19 PBT121.6999.72 22 NP90.9072.07 26 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Board of Procter & Gamble Health recommends interim dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
The company's revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year. Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review. Milind Thatte, Managing Director, P&G Health India, said, 'This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.' Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Procter & Gamble Health announces board meeting date
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
P&G Health hits 52 week high as Q2 PAT jumps 26% YoY to Rs 82 cr
Profit before tax in Q2 FY25 stood at Rs 111.4 crore, up 26.51% as against Rs 88.05 crore posted in same quarter last year. Total expenses were at Rs 205.29 crore in Q2 September 2024, down 7.91% on YoY basis. Cost of materials consumed stood at Rs 48.17 crore (down 44.82% YoY) while employee benefits expenses came in at Rs 46.22 crore (down 23.77% YoY) during the period under review. Milind Thatte, Managing Director, P superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization'. He further added, 'We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholders. We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness'. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The counter has hit a 52-week high at Rs 5,730.75 in today's intra-day session.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 25.56% in the September 2024 quarter
Net profit of Procter & Gamble Health rose 25.56% to Rs 82.33 crore in the quarter ended September 2024 as against Rs 65.57 crore during the previous quarter ended September 2023. Sales rose 2.78% to Rs 313.41 crore in the quarter ended September 2024 as against Rs 304.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales313.41304.93 3 OPM %36.3929.08 - PBDT117.1794.53 24 PBT111.4088.05 27 NP82.3365.57 26 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Procter & Gamble Health to hold board meeting
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant